Insider Selling: Eli Lilly and Company (NYSE:LLY) EVP Sells 5,000 Shares of Stock

Eli Lilly and Company (NYSE:LLY) EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eli Lilly and Company Trading Up 3.7%

Shares of LLY traded up $44.29 during trading hours on Monday, hitting $1,230.00. 2,928,651 shares of the stock traded hands, compared to its average volume of 3,143,000. The business has a fifty day moving average of $1,159.38 and a 200-day moving average of $1,047.62. The firm has a market capitalization of $1.16 trillion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $625.90 and a 1-year high of $1,249.45. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the previous year, the company earned $6.31 EPS. Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts expect that Eli Lilly and Company will post 36.77 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 23.22%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Eagle Health Investments LP acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $2,392,000. Essential Partners LLC raised its position in Eli Lilly and Company by 26.6% during the second quarter. Essential Partners LLC now owns 371 shares of the company’s stock valued at $445,000 after purchasing an additional 78 shares in the last quarter. Empirical Asset Management LLC boosted its stake in Eli Lilly and Company by 36.7% in the second quarter. Empirical Asset Management LLC now owns 4,661 shares of the company’s stock valued at $5,591,000 after buying an additional 1,252 shares in the last quarter. Sound Financial Strategies Group LLC bought a new stake in Eli Lilly and Company during the 2nd quarter worth $203,000. Finally, Chancellor Financial Group WB LP boosted its stake in shares of Eli Lilly and Company by 1.7% during the second quarter. Chancellor Financial Group WB LP now owns 918 shares of the company’s stock valued at $1,101,000 after purchasing an additional 15 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q2 results substantially exceeded expectations. Lilly reported $22.97 billion in second-quarter revenue, up 47.7% year over year, while adjusted earnings of $8.38 per share exceeded consensus by $1.98. The company raised its 2026 outlook, including a midpoint revenue target of approximately $86 billion and adjusted EPS guidance of $35.50 to $36.50. LLY Q2 Deep Dive: Key Products and Pipeline Expansion
• Positive Sentiment: The obesity-drug opportunity remains the main growth catalyst. Analysts argue that Lilly’s next leg of growth could come from an oral obesity treatment, potentially expanding access through additional prescribers and payers beyond injectable therapies. Lilly’s expected regulatory filing timeline also increases competitive pressure on Novo Nordisk in the GLP-1 market. Eli Lilly Stock’s Next Climb Runs Through a Pill, Not Just an Injection
• Positive Sentiment: Lilly is broadening its pipeline beyond diabetes and obesity. Its olomorasib cancer drug received FDA Breakthrough Therapy designation for certain patients with advanced pancreatic cancer, and Lilly entered a trial collaboration to evaluate the drug in lung cancer. The company also participated in Remedium Bio’s $10 million Series A financing, supporting potential future biotechnology partnerships. Eli Lilly Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens
• Neutral Sentiment: Investor expectations are elevated. Lilly’s strong growth and leadership in GLP-1 drugs have made it a preferred “top dog” for investors, but its premium valuation leaves the stock sensitive to execution, regulatory, reimbursement, and competitive developments. Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on LLY shares. BMO Capital Markets reiterated an “outperform” rating and issued a $1,400.00 price objective on shares of Eli Lilly and Company in a report on Thursday. UBS Group set a $1,376.00 target price on Eli Lilly and Company in a research report on Friday. Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Finally, Guggenheim boosted their price objective on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,292.18.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.